Zhongguancun Qian Incubation Innovation Center Files Prospectus Highlighting Breakthrough Biotech Cluster in Haidian, Beijing

Gelonghui December 7 | According to Beijing Daily, Beijing Yinnuo Medical Technology Co., Ltd., which developed the first atherosclerosis-specific drug to enter clinical trials, Beijing Yimiaoshenzhou Medical Techology Co., Ltd., which obtained Beijing's first CAR-T cell therapy "Drug Production License," and CytoNiche, which pioneered an internationally innovative large-scale stem cell expansion process based on 3D cell microcarriers… As of now,ZhongguancunThe pre-incubation innovation center has nurtured more than 30 incubated enterprises, with over 95% concentration in the pharmaceuticals and health industry. Annual revenue has grown from less than 100 million yuan to over 600 million yuan, with an annual compound growth rate exceeding 100%. Corporate tax payments have increased from less than 2 million yuan to over 50 million yuan.